Patients with hematologic malignancies face significantly higher short- and long-term risk for cardiovascular disease vs the general public.

Olorofim has the potential to be particularly beneficial to patients with hematologic malignancies infected with Invasive ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with ...

In this free webinar, gain insight into new changes in molecular reclassification of hematologic malignancies and their effects in precision medicine. Attendees will learn about the use of molecular ...

According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta ...

Patients with hematologic malignancies are at high risk of thrombotic or hemorrhagic complications. The incidence of these events is greatly variable and is influenced by many factors, including the ...

Please provide your email address to receive an email when new articles are posted on . Hematologic parameters appeared to be “more accurate” than symptoms and signs when diagnosing infectious ...

Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer Patients with WDTC were identified from ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and ...